arrow
A

Alessia Tieghi

Azienda USL-IRCCS di Reggio Emilia
H指数:33
被引数:4,398

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Multi-parametric profiling of plasma-derived extracellular vesicles reveals a disease-associated molecular signature supporting a liquid biopsy approach in myelofibrosis

血浆来源的细胞外囊泡的多参数分析揭示了一种与疾病相关的分子特征,支持在骨髓纤维化中进行液体活检的方法

2026-04-110
OAAI
Revised “iRR6” model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib

修订后的“iRR6”模型在风险分层为1级的骨髓纤维化患者中使用鲁索利替尼治疗

Cancer
IF5.1
2025-08-210
OAAI
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design

探讨真性红细胞增多症的血栓栓塞危险因素:从现有证据到PROSPERO研究设计

2025-07-180
OA
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea

真性红细胞增多症患者使用一线羟基脲治疗时,ELN临床体征和症状对血栓风险的影响

Leukemia
IF13.4
2025-05-280
OAAI
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis

疾病表型显著影响慢性期骨髓纤维化患者停用鲁索利替尼后的结局

2025-03-040
OAAI
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
2025-01-200
OAAI
Clinical Implications of Plasma-Derived Extracellular Vesicles in Myeloproliferative Neoplasms: Unveiling Inflammatory Potential and Biomarkers for Cancer Treatment

血浆来源细胞外囊泡在骨髓增殖性肿瘤中的临床意义:揭示其炎症潜能及癌症治疗的生物标志物

BLOOD
IF23.1
2024-11-050
PRE
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study
CANCER
IF5.1
2024-07-301
OAAI
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy
CANCER
IF5.1
2023-12-284
OAAI
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
2023-05-030
OAAI
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
CANCER
IF5.1
2023-03-1821
OAAI
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis
CANCER
IF5.1
2022-04-018
OAAI
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome
CANCER
IF5.1
2021-04-0119
OAAI
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients

合并症和体重指数对真性红细胞增多症患者预后的影响

2021-03-0813
PREAI
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Ruxolitinib停药综合征: 251骨髓纤维化患者的发病率,危险因素和管理

2021-01-0744
OAAI
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

ruxolitinib治疗的589骨髓纤维化患者进展到爆炸期和结局的危险因素: 真实世界数据

2020-04-2019
OAAI
Second cancers in MPN: Survival analysis from an international study

MPN中的第二癌症: 一项国际研究的生存分析

2019-12-2232
OAAI
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
CANCER
IF5.1
2019-12-20121
OAAI
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib
2019-06-075
PREAI